Exelixis Stock News

Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.

Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.

Corporate results, both actual and predicted, spurred trading in Monday''s pre-market action

Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.

Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the three major averages recorded losses last week. Investors are awaiting earnings results from Commercial M

Exelixis (EXEL) gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic.

Exelixis (EXEL) gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview

These cheap stocks are trading at highly attractive prices and have the potential to break through this year. The post 7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now appeared first on Invest

Bender Robert & Associates decreased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 96.4% during the third quarter, HoldingsChannel reports. The firm owned 2,626 shares of the biotechnology company’s stock after selling 70,589 shares during the quarter. Bender Robert & Associates’ holdings in Exelixis were worth $256,000 at the end of the most recent […]

- Successful nomination of lead SAFEbody candidates triggers milestone payment - SAN DIEGO and SUZHOU, China, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ: ADAG ), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced achievement of a key milestone in its ongoing collaboration with Exelixis for development of novel masked antibody-drug conjugate (ADC) candidates leveraging Adagene''s proprietary SAFEbody precision masking technology. Under the terms of a collaboration and licensing agreement established in early 2021, Adagene will receive a $3 million milestone payment for successful nomination of lead SAFEbody candidates for one of its collaboration programs. "We are extremely proud of successfully providing lead SAFEbody candidates to Exelixis following the start of our collaboration earlier this year. Exelixis'' selection of these lead candidates further validates our proprietary SAFEbody technology and highlights the prowess of our overall DPL platform," said Peter Luo, Ph.D., Co-founder, Chief Executive Officer, and Chairman of Adagene. "Our SAFEbody masking technology is receiving clinical validation in our ongoing clinical trial from our anti-CTLA-4 monoclonal antibody program, and also marks a potential paradigm shift in the way a highly potent modality such as ADCs can be designed and developed, ultimately helping to improve the lives of patients suffering from cancer and other debilitating diseases." Under the terms of the agreement, Adagene received an upfront payment of $11 million and Exelixis can nominate two targets for development

Huntington National Bank raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 156.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,433 shares of the biotechnology companys stock after acquiring an additional 874 shares during the period. Huntington National Banks []

Exelixis, Inc. (NASDAQ:EXEL) EVP Peter Lamb sold 47,500 shares of Exelixis stock in a transaction that occurred on Wednesday, December 15th. The shares were sold at an average price of $17.44, for a total value of $828,400.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Peter Lamb []